Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2609-2615

  Marini, Francesca ^a   Falchetti, Alberto ^a   Silvestri, Sandra ^a   Bagger, Yu ^a   Luzi, Ettore ^a   Tanini, Annalisa ^a   Christiansen, Claus ^a   Brandi, Maria Luisa ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Amino bisphosphonates; Bone Mineral Density (BMD); Bone turnover markers; Farnesyl pyrophosphate synthase gene (FDPS); Gene polymorphisms

Indexed keywords

ADENOSINE; ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CYTOSINE; GENOMIC DNA; GERANYLTRANSFERASE; IBANDRONIC ACID; OSTEOCALCIN; PLACEBO;

ADULT; ALLELE; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DISEASE MARKER; DNA EXTRACTION; DOUBLE BLIND PROCEDURE; ENZYME METABOLISM; FEMALE; FEMUR; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SPINE; TREATMENT DURATION;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; FEMALE; GENOTYPE; GERANYLTRANSTRANSFERASE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE;

EID: 53349101679     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802352894     Document Type: Article

References (33)

1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36
2. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82
3. Melton 3rd LJ, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33
4. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006;354: 2250-61
5. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26
6. Delmas PD, Recker RR, Chesnut 3rd CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8
7. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;118:1051-6
8. Brier K, Roux C. What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring? Best Pract Res Clin Rheumatol. 2005;19:951-64
9. Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004;4:50-63
10. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005;17:462-6
11. Palomba S, Numis FG, Mossetti G, et al. Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clin Endocrinol (Oxf) 2003;58:365-71
12. Marc J, Prezelj J, Kernel R, et al. VDR genotype and response to etidronate therapy in late post-menopausal women. Osteoporos Int 1999;10:303-6
13. Arko B, Prezelj J, Komel R, et al. No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2002;81:147-52
14. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58
15. Luckman SP, Coxon FP, Ebetino FH, et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-78
16. Benford HL, Frith JC, Auriola S, et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-40
17. Van Beek E, Pieterman E, Cohen L, et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen- containing bisphosphonates. Biochem Biophys Res Commun 1999;264: 108-11
18. Ferlazzo V, Sferrazza C, Caccamo N, et al. In vitro effects of aminobisphosphonates on Vgamma9Vdelta2T cell activation and differentiation. Int J Immunopathol Pharmacol 2006; 19:309-17
19. Carbonell Sala S, Masi L, Marini F, et al. Genetics and pharmacogenetics of osteoporosis. J Endocrinol Invest 2005;28:2-7
20. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006;6:307-12
21. Carbonell Sala S, Falchetti A, Martineti V, et al. Intron 1 polymorphism (A/C) of FDPS gene: a new genetic marker for N-BPs therapy response? Proceeding of The ASBMR XXVII Annual Meeting, Nashville, USA, 2005, Abstract SA121. J Bone Miner Res 2005;20:1-512
22. Haga H, Yamada R, Ohnishi Y, et al. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. J Hum Genet 2002; 47:605-10
23. Bagger YZ, Tankó LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-35
24. Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998; 44:2290-300
25. Rosenquist C, Qvist P, Bjarnason N, et al. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 1995;41:1439-45
26. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128:253-61
27. Eastell R, Hannon RA, Garnero P, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 2007;22:1656-60
28. Calis KA, Pucino F. Zoledronic acid and secondary prevention of fractures. N Engl J Med 2007;357:1861-2
29. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006;116:115-20
30. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75
31. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895-6
32. Saltman LH, Javed A, Ribadeneyra J, et al. Organization of transcriptional regulatory machinery in osteoclast nuclei: compartmentalization of runx1. J Cell Physiol 2005;204:871-80
33. Levy ME, Parker Ra, Ferrell RE, et al. Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. Maturitas 2007;57:247-52